317 related articles for article (PubMed ID: 26986934)
1. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
Venkatesan S; Lamfers ML; Dirven CM; Leenstra S
CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.
Venkatesan S; Hoogstraat M; Caljouw E; Pierson T; Spoor JK; Zeneyedpour L; Dubbink HJ; Dekker LJ; van der Kaaij M; Kloezeman J; Berghauser Pont LM; Besselink NJ; Luider TM; Joore J; Martens JW; Lamfers ML; Sleijfer S; Leenstra S
Oncotarget; 2016 Sep; 7(36):58435-58444. PubMed ID: 27533080
[TBL] [Abstract][Full Text] [Related]
3. Network pharmacology of glioblastoma.
Aguda BD
Curr Drug Discov Technol; 2013 Jun; 10(2):125-38. PubMed ID: 23237675
[TBL] [Abstract][Full Text] [Related]
4. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.
Höland K; Salm F; Arcaro A
Curr Cancer Drug Targets; 2011 Oct; 11(8):894-918. PubMed ID: 21861842
[TBL] [Abstract][Full Text] [Related]
5. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
6. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
Bhusare N; Kumar M
Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
[TBL] [Abstract][Full Text] [Related]
7. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
[TBL] [Abstract][Full Text] [Related]
8. The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma.
Su CC; Wang MJ; Chiu TL
Int J Mol Med; 2010 Aug; 26(2):217-24. PubMed ID: 20596601
[TBL] [Abstract][Full Text] [Related]
9. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
Haluska F; Pemberton T; Ibrahim N; Kalinsky K
Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
[TBL] [Abstract][Full Text] [Related]
10. Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
[TBL] [Abstract][Full Text] [Related]
11. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted therapy of glioblastoma.
Le Rhun E; Preusser M; Roth P; Reardon DA; van den Bent M; Wen P; Reifenberger G; Weller M
Cancer Treat Rev; 2019 Nov; 80():101896. PubMed ID: 31541850
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma--a moving target.
Westermark B
Ups J Med Sci; 2012 May; 117(2):251-6. PubMed ID: 22512247
[TBL] [Abstract][Full Text] [Related]
14. Using the molecular classification of glioblastoma to inform personalized treatment.
Olar A; Aldape KD
J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
[TBL] [Abstract][Full Text] [Related]
15. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
16. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
17. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
18. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
Lackner MR
Expert Rev Mol Diagn; 2010 Jan; 10(1):75-87. PubMed ID: 20014924
[TBL] [Abstract][Full Text] [Related]
19. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma targeted therapy: updated approaches from recent biological insights.
Touat M; Idbaih A; Sanson M; Ligon KL
Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
